Search
ZD4407
go.drugbank.com/drugs/DB06539ExperimentalIt entered Phase 1 clinical trials for chronic obstructive pulmonary disease (COPD) in the United Kingdom but was discontinued during this phase in March 2003 … The drug ZD4407, an antiasthmatic developed by AstraZeneca, functions as a 5-lipoxygenase inhibitor.
Pemivibart
go.drugbank.com/drugs/DB18720Investigational[L50326] It received emergency use authorization (EUA) from the FDA in March 2024 for pre-exposure prophylaxis (PrEP) of COVID-19 in certain high-risk patient populations. … Pemivibart (Pemgarda) is a human IgG1 monoclonal antibody targeting the SARS-CoV-2 spike protein receptor binding domain.
Naldemedine
go.drugbank.com/drugs/DB11691ApprovedInvestigationalNaldemedine is an opioid receptor antagonist [FDA Label]. … It is a modified form of [DB00704] to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier.
Aripiprazole lauroxil
go.drugbank.com/drugs/DB14185ApprovedIt is a prodrug of [aripiprazole], which acts as a partial agonist at the D2 and 5-HT1A receptors, and as an antagonist at the 5-HT2A receptors [A34289]. … pathway activating D2 receptors, whereas negative symptoms may result from a decreased activity in the mesocortical dopaminergic pathway with D1 receptors predominating [T28].
Acetylcysteine
go.drugbank.com/drugs/DB06151ApprovedInvestigational[A228158,A228163,A228168] Acetylcysteine was granted FDA approval on 14 September 1963.[L31488] … [L31378,L31383,L31388,L31478] Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results.
Mixtures: N-ACETILCISTEÍNA MAS GUAYACOLATO DE GLICERILO, ACETILCISTEINA GUAYACOLATO DE GLICERILO JARABECategories: Compounds used in a research, industrial, or household settingCefiderocol
go.drugbank.com/drugs/DB14879ApprovedInvestigationalCefiderocol is a cephalosporin antibacterial drug and exerts a mechanism of action similar to other β-lactam antibiotics. … [FDA Label] This indication was supported by a positive clinical trial composed of 448 patients with complicated urinary tract infections which demonstrated a 72.6% rate of symptom resolution and bacterial
Categories: Compounds used in a research, industrial, or household settingPolymyxin B
go.drugbank.com/drugs/DB00781ApprovedInvestigationalVet approvedPolymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line[A176429]. … Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxic[A176426,FDA Label].
Mixtures: Dr Bells Pomade, Pomada De La Campana Triple Antibiotic Pain ReliefZanubrutinib
go.drugbank.com/drugs/DB15035ApprovedInvestigationalIn August 2021, the FDA granted accelerated approval to zanubrutinib for the treatment of adults with Waldenström’s macroglobulinemia.[L39030] This indication is valid in the US, Europe, and Canada. … L10166] which measures the proportion of patients in a trial whose tumour is entirely or partially destroyed by a drug.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic IndexVilobelimab
go.drugbank.com/drugs/DB16416ApprovedInvestigationalVilobelimab is a chimeric monoclonal immunoglobulin G4 (IgG4) antibody that binds to the soluble form of human C5a with high affinity. … It consists of mouse anti-human complement factor 5a (C5a) monoclonal binding sites (variable regions of heavy and light chain regions) and human gamma 4 heavy chain and light kappa chain constant regions
Rosuvastatin
go.drugbank.com/drugs/DB01098ApprovedInvestigational[A181397, A181403] While all statin medications are considered equally effective from a clinical standpoint, rosuvastatin is considered the most potent; doses of 10 to 40mg rosuvastatin per day were … of death in high-income countries and a major cause of morbidity around the world.
Products: ROVARIL® 10 MG CAPSULAS BLANDAS DE GELATINA, ROSU 1A PHARMA 5MG